INTRODUCTION AND OBJECTIVES: Lymph node (LN)
dissection has a significant impact on the oncologic outcomes of patients with prostate cancer. Previously, we have reported that the Prostatic Anterior Fat Pad Lymph Node (PAFP LN) may be a landing zone for prostate cancer metastasis and that, in the intermediate term, there was an equivalent duration of BCR free survival between patients with metastasis to the PAFP LNs and pelvic LNs. We sought to further investigate the oncologic significance of PAFP metastasis by analyzing the long-term outcomes of prostate cancer patients who underwent radical prostatectomy (RP) and were upstaged on the basis of PAFP LN dissection.
METHODS: A retrospective chart review of all robotic RPs performed at a single institution from June 2010 to July 2018 was conducted. Patients with positive PAFP LNs (PAFPþ) or positive pelvic LNs (PLNþ) were identified while excluding patients undergoing clinical trials and patients with incomplete data. Oncologic outcomes including prostate-specific antigen (PSA), Gleason score (GS), tumor grade, and margin status were collected. Outcomes were analyzed using Student T-Tests, Chi-Squared tests, and ANOVA statistical tests. KaplanMeier survival curves were generated to compare the time elapsed before biochemical recurrence (BCR) in PAFP LNþ versus PLNþ patients.
RESULTS: 1,340 patients undergoing robotic RP were identified. Of these, 7 (0.52%) were PAFPþ, 29 (2.16%) were PLNþ and 1 (0.07%) was PAFPþ/PLNþ. Pre-operative mean PSA score was significantly lower in the PAFPþ group than the PLNþ group (pvalue [ 0.018). There were no significant differences between the PAFPþ and PLNþ groups in the other clinico-demographic variables (BMI, GS (Biopsy or Pathologic), margin status). Kaplan-Meier curves indicated that there was no significant difference in BCR between the PAFPþ and PLNþ patients (p-value [ 0.0507).
CONCLUSIONS: The rates of BCR at 24 months between the PAFPþ and PLNþ patients were not statistically different. This suggests that PAFP positivity is a significant adverse pathologic finding similar to PLN positivity. Future work should aim to further delineate long-term risk of BCR and oncologic outcomes. Orthotopic neobladder (NB) offers patients distinct advantages over an ileal conduit for urinary diversion following radical cystectomy. These include the potential for near-normal voiding function, continence and a more acceptable body image. Long-term patient satisfaction, however, may be compromised by urinary functional outcomes and complications. This study aims to assess the long-term functional outcomes and complication rates of those undergoing orthotopic Studer NB urinary diversion. METHODS: Out of 721 patients from 1995 to 2017 who underwent cystectomy by 2 surgeons at our institution for bladder malignancy, 104 patients with orthotopic NB were identified. Our inclusion criteria were those who had > 1 year post-operative follow-up with sufficient data for analysis. The outcomes collected retrospectively were: post-operative complications, prevalence of long-term voiding dysfunction, anatomical, metabolic and functional outcomes related to NBs.
RESULTS: 66 patients with complete data were used for indepth analysis. Median follow-up was 6 years. 25 (37.9%) postoperative complications occurred: 2 (3%) Clavien III, and 1 (1.5%) Clavien IV. 30 (43.5%) patients reported nocturnal urinary incontinence (UI), 9 (13%) reported daytime UI requiring pads, 16 (23.2%) were utilizing clean intermittent catheterization and 3 had permanent drainage (4%; 1 suprapubic and 2 with indwelling urethral catheter). NB patients with greater than 5 years follow-up were more likely to have nocturnal UI (p[0.02). Moreover, 22 (31.9%) had recurrent UTIs, 12 (17.4%) had urolithiasis, 4 (6.1%) had vitamin B12 deficiency, and 3 (4.5%) required oral bicarbonate therapy. 1 (1.5%) patient developed end stage renal failure while 12 (18.8%) had milder degrees of renal insufficiency. Of the 12 (18.8%) uretero-NB stenosis, 7 underwent balloon dilation, of which 2 failed and required reimplantation; 2 were due to tumor recurrence and managed with palliative nephrostomy. All of the 5 (7.2%) NB-urethral contractures were managed endoscopically.
CONCLUSIONS: At our center, orthotopic NB is a safe option (low Clavien >III complication rate) with acceptable long-term functional outcomes. Although, this study lacks detailed urodynamic assessment, it can be assumed that chronic over-distension leading to NB hypotonia was the main problem. Risk of nocturnal UI increases with time (>5 years), and may be mitigated by frequent micturition. These long-term functional outcomes findings should be part of the pre-operative counselling for orthotopic NB.
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Fabian Obrecht*, Orlando Burkhardt, Christoph Schregel, Marco Randazzo, Christian Padevit, Hubert John, Winterthur, Switzerland INTRODUCTION AND OBJECTIVES: Robot-assisted cystectomy with complete intracorporeal reconstruction (iRARC) is an emerging procedure with encouraging long-term oncologic results. However urodynamic and functional data of patients undergoing iRARC are still limited. In this study, we describe the short-term functional and urodynamic results of the modified Studer neobladder after iRARC.
METHODS: We retrospectively assessed 12 consecutive male patients who underwent iRARC with Studer neobladder between November 2015 and November 2017. All patients were seen 1 year after iRARC for a urodynamic evaluation (cystomanometry, urethral pressure profilometry, pressure flow study and postvoid residual). Data on continence and quality of life were obtained by questionnaires (ICIQ, EORTC-BLM30 and other). Laboratory data was collected from our prospective registry. The study protocol was approved by local ethics board and all patients provided informed consent. We used descriptive statistics and Wilcoxon test to compare creatinine levels. Metric variables are displayed in median and range.
RESULTS: Median follow-up time in this series was 11 (7-16) months after iRARC. All patients were socially continent ( 1 pad) at daytime. At night 5/12 (42%) needed no pads, 4/12 (33%) needed 1 pad and 3/12 (25%) needed >1 pad. Median Pouch capacity was 404 (253-670) ml with a median postvoid residual volume of 0 (0 -30) ml. Maximal Flow Rate (Qmax) was at a median of 19.6 (7.3 -43.2) ml per Vol. 201, No. 4S, Supplement, Sunday, May 5, 2019 THE JOURNAL OF UROLOGY Ò e877
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